Issues in clinical trial methodology for brain repair after stroke

Brain Repair After Stroke

Volumn , Issue , 2010, Pages 173-182

  Cramer, Steven C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960270135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511777547.017     Document Type: Chapter

References (136)

1. Yue NC, Longstreth WT Jr., Elster AD, et al. Clinically serious abnormalities found incidentally at MR imaging of the brain: Data from the Cardiovascular Health Study. Radiology. 1997;202:41-6.
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119:480-6.
3. Reed S, Cramer S, Blough D, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001;32:1832-40.
4. Katzan I, Furlan A, Lloyd L, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA. 2000;283:1151-8.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
6. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-11.
7. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: The EXCITE randomized clinical trial. JAMA. 2006;296:2095-104.
8. Wolf SL, Winstein CJ, Miller JP, etal. Retention of upper limb function in stroke survivors who have received constraint-induced movement therapy: The EXCITE randomised trial. Lancet Neurol. 2008;7:33-40.
9. Savitz SI, Fisher M. Future ofneuroprotection for acute stroke: In the aftermath of the SAINT trials. Ann Neurol. 2007;61:396-402.
10. Uchino K, Billheimer D, Cramer S. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke. 2001;32:909-16.
11. Duncan P, Jorgensen H, Wade D. Outcome measures in acute stroke trials: A systematic review and some recommendations to improve practice. Stroke. 2000;31:1429-38.
12. Toth G, Albers GW. Use of MRI to estimate the therapeutic window in acute stroke: Is perfusion-weighted imaging/diffusion-weighted imaging mismatch an EPITHET for salvageable ischemic brain tissue? Stroke. 2009;40:333-5.
13. Donnan GA, Baron JC, Ma H, et al. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009;8:261-9.
14. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case: A Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28:217-9.
15. Cramer S, Benson R, Burra V, et al. Mapping individual brains to guide restorative therapy after stroke: Rationale and pilot studies. Neurol Res. 2003;25:811-4.
16. Cramer SC, Parrish TB, Levy RM, et al. Predicting functional gains in a stroke trial. Stroke. 2007;38:2108-14.
17. Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. NeuroImage. 2006;33:913-22.
18. Stinear CM, Barber PA, Smale PR, et al. Functional potential in chronic stroke patients depends on corticospinal tract integrity. Brain. 2007;130:170-80.
19. Dromerick A, Lang C, Powers W, et al. Very Early Constraint-Induced Movement Therapy (VECTORS): Phase II trial results. Stroke. 2007;38:465.
20. Cramer S, Dobkin B, Noser E, et al. A randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Stroke. 2009;40:3034-8.
21. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: A logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-94.
22. Ovbiagele B, Kidwell CS, Starkman S, et al. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003;3:9-20.
23. Kozlowski D, Jones T, Schallert T. Pruning of dendrites and restoration of function after brain damage: Role of the NMDA receptor. Restor Neurol Neurosci. 1994;7:119-26.
24. Wahlgren N, Martinsson L. New concepts for drug therapy after stroke. Can we enhance recovery?Cerebrovasc Dis. 1998;8(5): 33-8.
25. Barth T, Hoane M, Barbay S, et al. Effects of glutamate antagonists on the recovery and maintenance of behavioral function after brain injury. In: Goldstein L, editor. Restorative neurology: Advances in pharmacotherapy for recovery after stroke. Armonk, NY: Futura Publishing Co., Inc.; 1998.
26. Grotta J, Bratina P. Subjective experiences of 24 patients dramatically recovering from stroke. Stroke. 1995;26:1285-8.
27. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol. 2003;53:10-20.
28. Gladstone D, Black S, Hakim A. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33:2123-36.
29. Fisher M, Feuerstein G, Howells DW, et al. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations. Stroke. 2009;40:2244-50.
30. Philip M, Benatar M, Fisher M, et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577-81.
31. Macleod MR, van der Worp HB, Sena ES, et al. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39:2824-9.
32. Goldberg MP, Ransom BR. New light on white matter. Stroke. 2003;34:330-2.
33. Cramer S. Clinical issues in animal models of stroke and rehabilitation. ILAR J. 2003;44:83-4.
34. Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. 2008;25:268-78.
35. Napieralski JA, Butler AK, Chesselet MF. Anatomical and functional evidence for lesion-specific sprouting of corticostriatal input in the adult rat. J Comp Neurol. 1996;373:484-97.
36. Voorhies A, Jones T. The behavioral and dendritic growth effects of focal sensorimotor cortical damage depend on the method of lesion induction. Behav Brain Res. 2002;133:237-46.
37. Windle V, Szymanska A, Granter-Button S, et al. An analysis of four different methods of producing focal cerebral ischemia with endothelin-1 in the rat. Exp Neurol. 2006;201:324-34.
38. Kwakkel G. Impact of intensity of practice after stroke: Issues for consideration. Disabil Rehabil. 2006;28:823-30.
39. Kwakkel G, Wagenaar R, Twisk J, et al. Intensity of leg and arm training after primary middle-cerebral-artery stroke: A randomised trial. Lancet. 1999;354:191-6.
40. Dobkin B. The clinical science ofneurologic rehabilitation. New York, NY: Oxford University Press; 2003.
41. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, et al.The impact of physical therapy on functional outcomes after stroke: What’s the evidence? Clin Rehabil. 2004;18:833-62.
42. Cicerone KD, Dahlberg C, Malec JF, et al. Evidence-based cognitive rehabilitation: Updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil. 2005;86:1681-92.
43. Bhogal S, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. Stroke. 2003;34:987-93.
44. Jones T, Chu C, Grande L, et al. Motor skills training enhances lesion-induced structural plasticity in the motor cortex of adult rats. J Neurosci. 1999;19:10 153-63.
45. Johansson B. Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke. 2000;31:223-30.
46. Gladstone DJ, Danells CJ, Armesto A, et al. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: A randomized, double-blind, placebo-controlled trial. Stroke. 2006;37:179-85.
47. Walker-Batson D, Smith P, Curtis S, et al.Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 1995;26:2254-9.
48. Macko RF, Haeuber E, Shaughnessy M, et al. Microprocessor-based ambulatory activity monitoring in stroke patients. Med Sci Sports Exerc. 2002;34:394-9.
49. Reiterer V, Sauter C, Klosch G, et al. Actigraphy - A useful tool for motor activity monitoring in stroke patients. Eur Neurol. 2008;60:285-91.
50. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann Neurol. 2008;63:272-87.
51. McFadden E, Luben R, Wareham N, et al. Social class, risk factors, and stroke incidence in men and women: A prospective study in the European prospective investigation into cancer in Norfolk cohort. Stroke. 2009;40:1070-7.
52. Smith J, Forster A, Young J. Cochrane review: Information provision for stroke patients and their caregivers. Clin Rehabil. 2009;23:195-206.
53. Glass TA, Matchar DB, Belyea M, et al. Impact of social support on outcome in first stroke. Stroke. 1993;24:64-70.
54. Lai SM, Duncan PW, Keighley J, et al. Depressive symptoms and independence in BADL and IADL. J Rehabil Res Dev. 2002;39:589-96.
55. Jonsson AC, Lindgren I, Hallstrom B, et al.Determinants of quality of life in stroke survivors and their informal caregivers. Stroke. 2005;36:803-8.
56. Mukherjee D, Levin RL, Heller W. The cognitive, emotional, and social sequelae of stroke: Psychological and ethical concerns in post-stroke adaptation. Topics Stroke Rehabil. 2006;13:26-35.
57. Nys GM, Van Zandvoort MJ, De Kort PL, et al.Domain-specific cognitive recovery after first-ever stroke: A follow-up study of 111 cases. J Int Neuropsychol Soc. 2005;11:795-806.
58. Kleim JA, Chan S, Pringle E, et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci. 2006;9:735-7.
59. Siironen J, Juvela S, Kanarek K, et al. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2858-60.
60. Alberts MJ, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral haemorrhage.Lancet. 1995;346:575.
61. Pearson-Fuhrhop KM, Kleim JA, Cramer SC. Brain plasticity and genetic factors. Top Stroke Rehabil. 2009;16:282-99.
62. Butefisch C, Davis B, Wise S, et al. Mechanisms of use-dependent plasticity in the human motor cortex. Proc NatlAcad Sci USA. 2000;97:3661-5.
63. Feeney D, Gonzalez A, Law W. Amphetamine, haloperidol, and experience interact to affect the rate of recovery after motor cortex injury. Science. 1982;217:855-7.
64. Goldstein L, Sygen in Acute Stroke Study Investigators. Common drugs may influence motor recovery after stroke. Neurology. 1995;45:865-71.
65. Troisi E, Paolucci S, Silvestrini M, et al. Prognostic factors in stroke rehabilitation: The possible role of pharmacological treatment. Acta Neurol Scand. 2002;105:100-06.
66. Conroy B, Zorowitz R, Horn SD, et al. An exploration of central nervous system medication use and outcomes in stroke rehabilitation. Arch Phys Med Rehabil. 2005;86(12-2):73-81.
67. Lazar R, Fitzsimmons B, Marshall R, etal. Reemergence of stroke deficits with midazolam challenge. Stroke. 2002;33:283-5.
68. Dromerick AW, Khader SA. Medical complications during stroke rehabilitation. Adv Neurol. 2003;92:409-13.
69. Kalra L, Yu G, Wilson K, et al. Medical complications during stroke rehabilitation. Stroke. 1995;26:990-4.
70. McLean D. Medical complications experienced by a cohort of stroke survivors during inpatient, tertiary-level stroke rehabilitation. Arch Phys Med Rehabil. 2004;85:466-9.
71. Berlowitz DR, Hoenig H, Cowper DC, et al. Impact of comorbidities on stroke rehabilitation outcomes: Does the method matter? Arch Phys Med Rehabil. 2008;89:1903-06.
72. Piantadosi S. Clinical trials. A methodologic perspective. New York, NY: John Wiley & Sons, Inc.; 1997.
73. Ozdemir O, Beletsky V, Chan R, et al. Thrombolysis in patients with marked clinical fluctuations in neurologic status due to cerebral ischemia. Arch Neurol. 2008;65:1041-3.
74. Volpe BT, Ferraro M, Lynch D, et al. Robotics and other devices in the treatment of patients recovering from stroke. Curr Neurol Neurosci Rep. 2005;5:465-70.
75. Scheidtmann K, Fries W, Muller F, et al. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomised, double-blind study. Lancet. 2001;358:787-90.
76. Gresham G, Duncan P, Stason W, et al. Post-stroke rehabilitation. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research; 1995.
77. Rathore S, Hinn A, Cooper L, et al. Characterization of incident stroke signs and symptoms: Findings from the Atherosclerosis Risk in Communities study. Stroke. 2002;33:2718-21.
78. Hier D, Mondlock J, Caplan L. Recovery of behavioral abnormalities after right hemisphere stroke. Neurology. 1983;33:345-50.
79. Marshall R, Perera G, Lazar R, et al. Evolution of cortical activation during recovery from corticospinal tract infarction. Stroke. 2000;31:656-61.
80. Markgraf C, Green E, Hurwitz B, et al. Sensorimotor and cognitive consequences of middle cerebral artery occlusion in rats. Brain Res. 1992;575:238-46.
81. Hillis A, Newhart M, Heidler J, et al. Anatomy ofspatial attention: Insights from perfusion imaging and hemispatial neglect in acute stroke. J Neurosci. 2005;25:3161-7.
82. Hillis A, Wityk R, Barker P, et al. Subcortical aphasia and neglect in acute stroke: The role of cortical hypoperfusion. Brain. 2002;125:1094-104.
83. Duncan PW, Zorowitz R, Bates B, et al. Management of adult stroke rehabilitation care: A clinical practice guideline. Stroke. 2005;36:e100-43.
84. Salter K, Jutai J, Zettler L, et al. Outcome measures in stroke rehabilitation. http://wwwebrsrcom/uploads/Outcome_Measures_SREBR11_finalpdf. 2008.
85. Collins JM. Functional imaging in phase I studies: Decorations or decision making? J Clin Oncol. 2003;21:2807-09.
86. Carey J, Kimberley T, Lewis S, et al. Analysis of fMRI and finger tracking training in subjects with chronic stroke. Brain. 2002;125:773-88.
87. Johansen-Berg H, Dawes H, Guy C, et al. Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. Brain. 2002;125:2731-42.
88. Koski L, Mernar T, Dobkin B. Immediate and longterm changes in corticomotor output in response to rehabilitation: Correlation with functional improvements in chronic stroke. Neurorehabil Neural Repair. 2004;18:230-49.
89. Temple R. A regulatory authority’s opinion about surrogate endpoints. In: Nimmo W, Tucker G, editors. Clinical measurement in drug evaluation. New York, NY: John Wiley and Sons; 1995.
90. Fleming T, DeMets D. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125:605-13.
91. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res. 2007;24:1172-85.
92. Lansberg MG, Thijs VN, Hamilton S, et al. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke. 2007;38:1826-30.
93. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-31.
94. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
95. Hsia A, Kidwell C. Magnetic resonance imaging for surrogate outcomes and patient selection. In: Woodbury-Harris K, Coull B, editors. Clinical trials in the neurosciences. Basel: Karger; 2009: pp. 89-92.
96. Boissel J, Collet J, Moleur P, et al. Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol. 1992;43:235-44.
97. Bucher H, Guyatt G, Cook D, et al. Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA. 1999;282:771-8.
98. Takahashi CD, Der-Yeghiaian L, Le V, et al. Robot-based hand motor therapy after stroke. Brain. 2008;131:425-37.
99. Bosnell R, Wegner C, Kincses ZT, et al. Reproducibility of fMRI in the clinical setting: Implications for trial designs. NeuroImage. 2008;42:603-10.
100. Eaton KP, Szaflarski JP, Altaye M, et al. Reliability of fMRI for studies of language in post-stroke aphasia subjects. NeuroImage. 2008;41:311-22.
101. Kimberley TJ, Khandekar G, Borich M. fMRI reliability in subjects with stroke. Exp Brain Res/Experimentelle Hirnforschung. 2008;186:183-90.
102. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes as a new prognostic marker in early cerebral stroke. J Neurol. 2007;254:617-23.
103. Yip HK, Chang LT, Chang WN, et al. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke. 2008;39:69-74.
104. Brott T, Marler J, Olinger C, et al. Measurements of acute cerebral infarction: Lesion size by computed tomography. Stroke. 1989;20:871-5.
105. Saver J, Johnston K, Homer D, et al. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke. 1999;30:293-8.
106. Schiemanck SK, Kwakkel G, Post MW, et al. Predictive value of ischemic lesion volume assessed with magnetic resonance imaging for neurological deficits and functional outcome poststroke: A critical review of the literature. Neurorehabil Neural Repair. 2006;20:492-502.
107. Schaechter JD, Moore CI, Connell BD, et al. Structural and functional plasticity in the somatosensory cortex of chronic stroke patients. Brain. 2006;129:2722-33.
108. Crafton K, Mark A, Cramer S. Improved understanding of cortical injury by incorporating measures of functional anatomy. Brain. 2003;126:1650-9.
109. Bocti C, Swartz RH, Gao FQ, et al. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke. 2005;36:2126-31.
110. Hillis AE, Gold L, Kannan V, et al. Site of the ischemic penumbra as a predictor of potential for recovery of functions. Neurology. 2008;71:184-9.
111. Ding G, Jiang Q, Li L, et al. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab. 2008;28:1440-8.
112. Hodics T, Cohen LG, Cramer SC. Functional imaging of intervention effects in stroke motor rehabilitation. Arch Phys Med Rehabil. 2006;87(12):36-42.
113. Richards LG, Stewart KC, Woodbury ML, et al.Movement-dependent stroke recovery: A systematic review and meta-analysis of TMS and fMRI evidence. Neuropsychologia. 2008;46:3-11.
114. Dong Y, Dobkin BH, Cen SY, et al. Motor cortex activation during treatment may predict therapeutic gains in paretic hand function after stroke. Stroke. 2006;37:1552-5.
115. Cramer S, Nelles G, Benson R, et al. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke. 1997;28:2518-27.
116. Naccarato M, Calautti C, Jones PS, et al. Does healthy aging affect the hemispheric activation balance during paced index-to-thumb opposition task? An fMRI study. NeuroImage. 2006;32:1250-6.
117. Grefkes C, Nowak DA, Eickhoff SB, et al. Cortical connectivity after subcortical stroke assessed with functional magnetic resonance imaging. Ann Neurol. 2008;63:236-46.
118. Parsons M, Li T, Barber P, et al. Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology. 2000;55:498-505.
119. Pendlebury S, Blamire A, Lee M, et al. Axonal injury in the internal capsule correlates with motor impairment after stroke. Stroke. 1999;30:956-62.
120. Nair DG, Hutchinson S, Fregni F, et al. Imaging correlates of motor recovery from cerebral infarction and their physiological significance in well-recovered patients. NeuroImage. 2007;34:253-63.
121. Ward NS, Newton JM, Swayne OB, et al. Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain. 2006;129:809-19.
122. Talelli P, Greenwood RJ, Rothwell JC. Arm function after stroke: Neurophysiological correlates and recovery mechanisms assessed by transcranial magnetic stimulation. Clin Neurophysiol. 2006;117:1641-59.
123. Powers W, Raichle M. Positron emission tomography and its application to the study of cerebrovascular disease in man. Stroke. 1985;16:361-76.
124. Heiss WD. Imaging the ischemic penumbra and treatment effects by PET. Keio J Med. 2001;50:249-56.
125. Ward NS. Neural plasticity and recovery of function. Prog Brain Res. 2005;150:527-35.
126. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
127. Albert ML. A simple test of visual neglect. Neurology. 1973;23:658-64.
128. Kent PS, Luszcz MA. A review of the Boston Naming Test and multiple-occasion normative data for older adults on 15-item versions. Clin Neuropsychol. 2002;16:555-74.
129. Alexander MP, Baker E, Naeser MA, et al.Neuropsychological and neuroanatomical dimensions of ideomotor apraxia. Brain. 1992;115: 87-107.
130. Wade DT. Measuring arm impairment and disability after stroke. Int Disabil Stud. 1989;11:89-92.
131. Yozbatiran N, Der-Yeghiaian L, Cramer SC. A standardized approach to performing the action research arm test. Neurorehabil Neural Repair. 2008;22:78-90.
132. Fugl-Meyer A, Jaasko L, Leyman I, et al. The poststroke hemiplegic patient: A method for evaluation of physical performance. Scand J Rehabil Med. 1975;7:13-31.
133. Richards C, Malouin F, Dumas F, et al. Gait velocity as an outcome measure of locomotor recovery after stroke. In: Craik R, Oates C, editors. Gait analysis: Theory and application. St. Louis: Mosby; 1995: pp. 355-64.
134. Lincoln N, Jackson J, Adams S. Reliability and revision of the Nottingham Sensory Assessment for stroke patients. Physiotherapy. 1998;84:358-65.
135. Agrell B, Dehlin O. Comparison of six depression rating scales in geriatric stroke patients. Stroke. 1989;20:1190-4.
136. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technique. Postgrad Med. 1972;52:81-5.